Mary Anne Meskis

Mary Anne was a founding member of DSF, stepping off of the Board to take the position of Executive Director in 2012. She is a passionate advocate for the Dravet syndrome community and has served in various capacities for the community prior to the inception of DSF in 2009. In addition, she currently serves on several epilepsy working groups, including the Epilepsy Leadership Council. She has owned and managed several small businesses in the private sector, spanning over 25 years. This business experience has translated well into her role as Executive Director. She is responsible for the overall organizational management and has continued to expand programming and fund development for DSF. Mary Anne resides in North Carolina with her husband and her youngest son, Elliot, who has Dravet syndrome. It is her son who drives her to be a catalyst for change within the Dravet syndrome community.

Avatar photo

What is RSS?

What is RSS To stay up to date with our latest blog posts and news articles, subscribe to our RSS feed. You’ll get a notification in your RSS feed reader as soon as we publish new updates about DSF. What is an RSS feed? An RSS feed is a list of articles that updates in

What is RSS? Read More »

DSF Homepage Dravet Family

Meredith Bankston Promoted to Event Coordinator

Dravet Syndrome Foundation (DSF) is excited to announce the promotion of Meredith Bankston to Event Coordinator. Meredith joined the organization in 2022 and has demonstrated dedication and skill in her previous role as Fundraising Assistant, leading to her advancement within the organization. In her new position, Meredith will play a crucial role in overseeing and

Meredith Bankston Promoted to Event Coordinator Read More »

An artificial intelligence/machine learning approach to predicting anti-seizure medication efficacy in Dravet syndrome

A major challenge in the management of many epilepsies, including Dravet syndrome (DS), is the prolonged trial and error approach of determining whether or not a specific antiseizure medication (ASM) will work for a given patient. Testing an add-on therapy can take many months before it is determined to be ineffective, and for some it

An artificial intelligence/machine learning approach to predicting anti-seizure medication efficacy in Dravet syndrome Read More »

Scroll to Top
Skip to content